Preliminary Phase 1b data is in line with Phase 1a data reported at the European Society of Medical Oncology in September 2025 Combined disease control rate of 90% across both Phase 1a and Phase 1b patients with confirmed partial and minor responses observed LONDON and PHILADELPHIA, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, today announced compelling new data in patients ...

Agreement Calls for Development Services and Tech Transfer in Preparation for Commercial Manufacturing of Injectable Pharmaceutical Product Partner’s Program Size Positions it to Become a Top Five Commercial Customer for Lifecore CHASKA, Minn., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has signed a CDMO master services agreement with a new large global pharm ...

MONTREAL, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Bombardier Inc. (“Bombardier”) today announced that it has issued a notice of partial redemption for US$500 million aggregate principal amount of its outstanding 6.000% Senior Notes due 2028 (the “2028 Notes”). As set forth in the notice of partial redemption issued today in respect of the 2028 Notes, the redemption date is February 15, 2026, and the redemption price for the 2028 Notes is 100% of the principal amount redeemed, plus accrued and unpaid interest. Thi ...

License Agreement grants Sagimet a global, exclusive license to innovative forms of resmetirom active pharmaceutical ingredient (API) developed by TAPI and covered by TAPI patent applicationsCollaboration supports Sagimet’s fixed-dose combination (FDC) program currently in clinical developmentSagimet’s Phase 1 pharmacokinetic (PK) trial of combination of denifanstat and resmetirom is underway with topline data anticipated by the end of 2025Sagimet anticipates selecting one of the innovative forms of resmeti ...

Not for dissemination in the United States or for distribution to U.S. Newswire Services VANCOUVER, British Columbia, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Xali Gold Corp. (TSXV:XGC) (“Xali Gold” or the “Company”) is pleased to announce that it plans to close the first tranche of the previously announced non–brokered private placement (the “Private Placement”) on December 19th, 2025, raising approximately C$1 Million. A second tranche of approximately C$0.5 Million is planned to close on or about Tuesday, Decem ...

AUSTIN, Texas, Dec. 17, 2025 (GLOBE NEWSWIRE) -- TTEC Holdings Inc. (NASDAQ: TTEC), a leading global CX (customer experience) technology and services innovator for AI-enabled CX, today announced that TTEC Digital has been recognized as a Leader and Star Performer in the 2025 Everest Group PEAK Matrix® Assessment for Digital Transformation Services for Mid-market Enterprises. Everest Group’s PEAK Matrix® is a renowned industry benchmark that measures impact in market adoption, portfolio mix, value, vision, ...

FRIENDSWOOD, Texas, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data from the largest prospective, multicenter study to date comparing next-generation sequencing (NGS)-based gene mutation analysis with the combination of DecisionDx-UM and Preferentially Expressed Antigen in Melanoma (PRAME) gene expression for predicting outcomes in patients with uveal melanoma (UM). The study, tit ...

Design phase contract is with a European specialist in radioactive waste processing and nuclear decommissioningMONTREAL, Dec. 17, 2025 (GLOBE NEWSWIRE) -- PyroGenesis Inc. (“PyroGenesis”) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY1), the leader in ultra-high temperature processes and engineering innovation, and a plasma-based technology provider to heavy industry & defense, announces today the recent signing of an initial design phase contract with a European organization specializing in radioactive waste processi ...

Evolve commence trading on the CSE today, December 17, 2025 under the ticker symbol “EVR” Not for distribution to United States newswire services or for release, publication, distribution or dissemination, directly or indirectly, in whole or in part, in or into the United States. TORONTO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Evolve Royalties Ltd. (CSE: EVR) (“Evolve” or the “Company”) is pleased to announce that its common shares have commenced trading on the Canadian Securities Exchange (the “CSE”) under the ...

WATERTOWN, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026 at 7:30 a.m. PT/10:30 a.m. ET. A webcast and subsequent archived replay of the prese ...